Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:53:57 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CAMP - CAMP4 THERAPEUTICS CORPORATION - https://www.calamp.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CAMP - Q0.13.15·5.005.03.84+0.257.040.91201,1793.65  3.98  3.657.29  1.30516:10:04Jan 1615 min RT 2¢

Recent Trades - Last 10 of 1179
Time ETExPriceChangeVolume
16:10:04Q3.840.251
16:10:04Q3.840.251
16:04:02Q3.840.251
16:00:31Q3.840.25269
16:00:18Q3.840.251
16:00:18Q3.840.251
16:00:03Q3.840.2521
16:00:03Q3.840.2558
16:00:03Q3.840.2560
16:00:03Q3.840.25202

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-16 16:05U:CAMPNews ReleaseCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 08:00U:CAMPNews ReleaseCAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-18 07:10U:CAMPNews ReleaseCAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
2025-12-18 07:00U:CAMPNews ReleaseCAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
2025-12-12 16:05U:CAMPNews ReleaseCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-14 16:05U:CAMPNews ReleaseCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-11-06 16:05U:CAMPNews ReleaseCAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
2025-10-01 08:00U:CAMPNews ReleaseCAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
2025-09-10 07:00U:CAMPNews ReleaseCAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
2025-08-14 16:05U:CAMPNews ReleaseCAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
2025-05-16 06:00U:CAMPNews ReleaseCAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Socie
2025-05-13 16:05U:CAMPNews ReleaseCAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
2025-04-28 16:30U:CAMPNews ReleaseCAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
2025-03-27 16:05U:CAMPNews ReleaseCAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
2025-03-18 08:00U:CAMPNews ReleaseCAMP4 Appoints Multiple Industry Veterans to its Board of Directors